Overview

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

Status:
Not yet recruiting
Trial end date:
2024-02-19
Target enrollment:
Participant gender:
Summary
The purpose of this study will be to evaluate Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus. This is randomized, double-blind, vehicle-controlled (DBVC) study with a DBVC period of 16 weeks followed by an open label period (OLE) period of 16 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation